1
|
Dash S, Langenberg C, Fawcett KA, Semple RK, Romeo S, Sharp S, Sano H, Lienhard GE, Rochford JJ, Howlett T, Massoud AF, Hindmarsh P, Howell SJ, Wilkinson RJ, Lyssenko V, Groop L, Baroni MG, Barroso I, Wareham NJ, O’ Rahilly S, Savage DB. Analysis of TBC1D4 in patients with severe insulin resistance. Diabetologia 2010; 53:1239-42. [PMID: 20349035 PMCID: PMC2860565 DOI: 10.1007/s00125-010-1724-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Accepted: 02/18/2010] [Indexed: 11/30/2022]
Affiliation(s)
- S. Dash
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| | - C. Langenberg
- MRC Epidemiology Unit, Institute of Metabolic Sciences, Addenbrooke’s Hospital, Cambridge, UK
| | - K. A. Fawcett
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK
| | - R. K. Semple
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| | - S. Romeo
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| | - S. Sharp
- MRC Epidemiology Unit, Institute of Metabolic Sciences, Addenbrooke’s Hospital, Cambridge, UK
| | - H. Sano
- Department of Biochemistry, Dartmouth Medical School, Hanover, NH USA
| | - G. E. Lienhard
- Department of Biochemistry, Dartmouth Medical School, Hanover, NH USA
| | - J. J. Rochford
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| | - T. Howlett
- Department of Diabetes and Endocrinology, Leicester Royal Infirmary, Leicester, UK
| | - A. F. Massoud
- Children’s Services, Northwick Park Hospital, Harrow, Middlesex, UK
| | - P. Hindmarsh
- London Centre for Paediatric Endocrinology and Metabolism, Cobbold Laboratories, Middlesex Hospital, London, UK
| | - S. J. Howell
- Department of Diabetes and Endocrinology, Royal Preston Hospital, Preston, UK
| | | | - V. Lyssenko
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - L. Groop
- Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - M. G. Baroni
- Department of Medical Sciences, Endocrinology and Metabolism, University of Cagliari, Cagliari, Sardinia Italy
| | - I. Barroso
- Metabolic Disease Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, UK
| | - N. J. Wareham
- MRC Epidemiology Unit, Institute of Metabolic Sciences, Addenbrooke’s Hospital, Cambridge, UK
| | - S. O’ Rahilly
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| | - D. B. Savage
- University of Cambridge Metabolic Research Laboratories, Level 4, Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital Box 289, Hills Road, Cambridge, CB2 0QQ UK
| |
Collapse
|
2
|
Franks PW, Rolandsson O, Debenham SL, Fawcett KA, Payne F, Dina C, Froguel P, Mohlke KL, Willer C, Olsson T, Wareham NJ, Hallmans G, Barroso I, Sandhu MS. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 2008; 51:458-63. [PMID: 18040659 PMCID: PMC2670195 DOI: 10.1007/s00125-007-0887-6] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Accepted: 10/30/2007] [Indexed: 02/07/2023]
Abstract
AIMS/HYPOTHESIS Mutations at the gene encoding wolframin (WFS1) cause Wolfram syndrome, a rare neurological condition. Associations between single nucleotide polymorphisms (SNPs) at WFS1 and type 2 diabetes have recently been reported. Thus, our aim was to replicate those associations in a northern Swedish case-control study of type 2 diabetes. We also performed a meta-analysis of published and previously unpublished data from Sweden, Finland and France, to obtain updated summary effect estimates. METHODS Four WFS1 SNPs (rs10010131, rs6446482, rs752854 and rs734312 [H611R]) were genotyped in a type 2 diabetes case-control study (n = 1,296/1,412) of Swedish adults. Logistic regression was used to assess the association between each WFS1 SNP and type 2 diabetes, following adjustment for age, sex and BMI. We then performed a meta-analysis of 11 studies of type 2 diabetes, comprising up to 14,139 patients and 16,109 controls, to obtain a summary effect estimate for the WFS1 variants. RESULTS In the northern Swedish study, the minor allele at rs752854 was associated with reduced type 2 diabetes risk [odds ratio (OR) 0.85, 95% CI 0.75-0.96, p=0.010]. Borderline statistical associations were observed for the remaining SNPs. The meta-analysis of the four independent replication studies for SNP rs10010131 and correlated variants showed evidence for statistical association (OR 0.87, 95% CI 0.82-0.93, p=4.5 x 10(-5)). In an updated meta-analysis of all 11 studies, strong evidence of statistical association was also observed (OR 0.89, 95% CI 0.86-0.92; p=4.9 x 10(-11)). CONCLUSIONS/INTERPRETATION In this study of WFS1 variants and type 2 diabetes risk, we have replicated the previously reported associations between SNPs at this locus and the risk of type 2 diabetes.
Collapse
Affiliation(s)
- P W Franks
- Department of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Fawcett KA, Wareham NJ, Luan J, Syddall H, Cooper C, O'Rahilly S, Day INM, Sandhu MS, Barroso I. PARL Leu262Val is not associated with fasting insulin levels in UK populations. Diabetologia 2006; 49:2649-52. [PMID: 17019603 PMCID: PMC2672784 DOI: 10.1007/s00125-006-0443-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2006] [Accepted: 08/03/2006] [Indexed: 11/27/2022]
Abstract
AIMS/HYPOTHESIS PARL, the gene encoding presenilins-associated rhomboid-like protein, maps to chromosome 3q27 within a quantitative trait locus that influences components of the metabolic syndrome. Recently, an amino acid substitution (Leu262Val, rs3732581) in PARL was associated with fasting plasma insulin levels in a US white population (N=1031). This variant was also found to modify the positive association between age and fasting insulin. The aim of this study was to test whether these findings could be replicated in two UK population-based cohorts. METHODS Participants from the Medical Research Council Ely and Hertfordshire cohort studies were genotyped for this variant using a SNaPshot primer extension assay and Taqman assay respectively. Full phenotypic and genotypic data were available for 3,666 study participants. RESULTS Based on a dominant model, we found no association between the Leu262Val polymorphism and fasting insulin levels (p=0.79) or BMI (p=0.98). We did not observe the previously reported interaction between age and genotype on fasting insulin (p=0.14). CONCLUSIONS/INTERPRETATION Despite having greater statistical power, our data do not support the previously reported association between PARL Leu262Val and fasting plasma insulin levels, a measure of insulin resistance. Our findings indicate that this variant is unlikely to be an important contributor to insulin resistance in UK populations.
Collapse
Affiliation(s)
- K A Fawcett
- Metabolic Disease Group, Wellcome Trust Sanger Institute, The Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK
| | | | | | | | | | | | | | | | | |
Collapse
|